ORIGINAL PAPER
The effect of L-carnitine therapy on anaemia therapy in paediatric patients on regular haemodialysis
1
Paediatric Department, Faculty of Medicine, Menoufia University, Egypt
2
Clinical Pathology Department, National Liver Institute, Menoufia University, Egypt
3
Lecturer in clinical pathology, National Liver Institute, Menoufia University, Egypt
Submission date: 2021-07-03
Final revision date: 2021-10-15
Acceptance date: 2021-11-05
Publication date: 2022-01-11
Pediatr Pol 2021;96(4):238-244
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Renal anaemia is a common complication of haemodialysis patients. Hyporesponsiveness to erythropoietin (EPO) has been known as an important factor in poor recombinant human erythropoietin efficacy in the treatment of renal anaemia. Moreover, an increased erythropoiesis resistance index (ERI) may be associated with inflammation and lead to an increased mortality. The aim of the study to study the effect of L-carnitine (LC) therapy on anaemia and erythropoietin therapy in paediatric patients on regular haemodialysis.
Material and methods:
This prospective study was conducted on 30 CKD paediatric patients on regular haemodialysis attending the haemodialysis unit in Menoufia University. They were classified into 2 groups: 15 CKD patients receiving oral L-carnitine (LC) in a dose of 100 mg/kg per day in 3 divided doses – maximum 3 g per day and erythropoietin therapy in a dose of 100-300 IU/kg 3 times per week, considered as group I, and 15 CKD patients receiving erythropoietin therapy only (group II). Patients were subjected to history taking, clinical examination, and laboratory investigations including CBC, pre- and post- dialysis serum urea. Creatinine, iron profile, Ca, phosphorus, intact parathormone, erythropoiesis-stimulating agent dose (ESA), and erythropoietin-resistance index (ERI) were calculated at the baseline and then on follow-up after 6 months.
Results:
There was a statistically significant increase in Hb level in patients receiving both L-carnitine and erythropoietin therapy (group I) when compared to patients receiving erythropoietin only (group II) after 6 months. Moreover, there was a significant decrease in the mean erythropoietin-stimulating agent (ESA) dose and erythropoietin-resistance index (ERI) in group I with mean ±SD of 95.12 IU/kg ±10.99 IU/kg, 229.59 ±21.95 IU/kg/g when compared to group II at 149.11 ±43.98 IU/kg, 360.15 ±71.105 IU/kg/g (p-value 0.00), respectively.
Conclusions:
L-carnitine may be used as an adjuvant therapy in paediatric haemodialysis patients to decrease the requirement of erythropoietin-stimulating agents (ESA) dosage and erythropoietin-resistance index (ERI) while maintaining adequate levels of serum haemoglobin.
Renal anaemia is a common complication of haemodialysis patients. Hyporesponsiveness to erythropoietin (EPO) has been known as an important factor in poor recombinant human erythropoietin efficacy in the treatment of renal anaemia. Moreover, an increased erythropoiesis resistance index (ERI) may be associated with inflammation and lead to an increased mortality. The aim of the study to study the effect of L-carnitine (LC) therapy on anaemia and erythropoietin therapy in paediatric patients on regular haemodialysis.
Material and methods:
This prospective study was conducted on 30 CKD paediatric patients on regular haemodialysis attending the haemodialysis unit in Menoufia University. They were classified into 2 groups: 15 CKD patients receiving oral L-carnitine (LC) in a dose of 100 mg/kg per day in 3 divided doses – maximum 3 g per day and erythropoietin therapy in a dose of 100-300 IU/kg 3 times per week, considered as group I, and 15 CKD patients receiving erythropoietin therapy only (group II). Patients were subjected to history taking, clinical examination, and laboratory investigations including CBC, pre- and post- dialysis serum urea. Creatinine, iron profile, Ca, phosphorus, intact parathormone, erythropoiesis-stimulating agent dose (ESA), and erythropoietin-resistance index (ERI) were calculated at the baseline and then on follow-up after 6 months.
Results:
There was a statistically significant increase in Hb level in patients receiving both L-carnitine and erythropoietin therapy (group I) when compared to patients receiving erythropoietin only (group II) after 6 months. Moreover, there was a significant decrease in the mean erythropoietin-stimulating agent (ESA) dose and erythropoietin-resistance index (ERI) in group I with mean ±SD of 95.12 IU/kg ±10.99 IU/kg, 229.59 ±21.95 IU/kg/g when compared to group II at 149.11 ±43.98 IU/kg, 360.15 ±71.105 IU/kg/g (p-value 0.00), respectively.
Conclusions:
L-carnitine may be used as an adjuvant therapy in paediatric haemodialysis patients to decrease the requirement of erythropoietin-stimulating agents (ESA) dosage and erythropoietin-resistance index (ERI) while maintaining adequate levels of serum haemoglobin.
REFERENCES (43)
1.
Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis 2018; 71: 423-435.
2.
Hazin MAA. Anemia in chronic kidney disease. Rev Assoc Med Bras 2020; 66 (Suppl 1): s55-s58.
3.
Kurella Tamura M, Vittinghoff E, Yang J. Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrol 2016; 17: 13.
4.
KDIGO (Kidney Disease Improving Global Outcomes). CKD work group. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150.
5.
Luo J, Jensen DE, Maroni BJ, et al. Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients. Am J Kidney Dis 2016; 68: 763–771.
6.
Santos EJF, Hortegal EV, Serra HO, et al. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study. Braz J Med Biol Res 2018; 51: e7288.
7.
Gillespie IA, Macdougall IC, Richards S, et al. Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study. Pharmacoepidemiol Drug Saf 2015; 24: 414-426.
8.
Golper TA, Goral S, Becker BN. CB L-carnitine treatment of anemia. Am J Kidney Dis 2003; 41: 27-34.
9.
Yilmaz MI, Solak Y, Covic A. Renal anemia of infammation: the name is self-explanatory. Blood Purif 2011; 32: 220-225.
10.
Kanbay M, Perazella MA, Kasapoglu B. Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010; 29: 1-12.
11.
Mercadal L, Coudert M, Vassault A, et al. L-carnitine treatment in incident hemodialysis patients: the multicenter, randomized, double-blinded, placebo-controlled CARNIDIAL trial. Clin J Am Soc Nephrol 2012; 7: 1836-1842.
12.
Bonomini M, Zammit V, Pusey CD, et al. Pharmacological use of L-carnitine in uremic anemia: has its full potential been exploited? Pharmacol Res 2011; 63: 157-164.
13.
Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307.
14.
Warady BA, Borum P, Stall C, et al. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 1990; 10: 109-114.
15.
Gagnadoux MF, Loirat C, Berthélémé JP, et al. Treatment of anemia in hemodialyzed children using recombinant human erythropoietin (Eprex). Results of a French multicenter clinical trial. Nephrologie 1994; 15: 207-211.
16.
Jindal KK, Manuel A, Goldstein MB. Percent reduction in blood urea concentration during hemodialysis (PRU): a simple and accurate method to estimate Kt/V urea. ASAIO Trans 1987; 33: 286-288.
17.
Basile C, Casino F, Lopez T. Percent reduction in blood urea concentration during dialysis estimates Kt/V in a simple and accurate way. Am J Kidney Dis 1990; 15: 40-45.
18.
Lowrie EG, Lew NL. The urea reduction ratio (URR) a simple method for evaluating hemodialysis treatment. Contemp Dial Nephrol 1991; 12: 11-20.
19.
Okazaki M, Komatsu M, Kawaguchi H, et al. Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purification 2014; 37: 106-112.
20.
Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study. Medicine (Baltimore) 2016; 95: e3872.
21.
Suzuki M, Hada Y, Akaishi M, et al. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease. Int Heart J 2012; 53: 238–243.
22.
Hauber B, Caloyeras J, Posner J, et al. Hemodialysis patients’ preferences for the management of anemia. BMC Nephrology 2017; 18: 253.
23.
Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrology 2017; 18: 345.
24.
Kim IY, Kim JH, Kim MJ, et al. Low 1,25-dihydroxyvitamin D level is associated with erythropoietin deficiency and endogenous erythropoietin resistance in patients with chronic kidney disease. Int Urol Nephrol 2018; 50: 2255-2260.
25.
Ogawa T, Nitta T. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol 2015; 185: 76-86.
26.
Arduini A, Bonomini M, Clutterbuck EJ, Laffan MA, Pusey CD. Effects of L-carnitine administration on erythrocyte survival in hemodialysis patients. Nephrol Dial Transplant. 2006; 21:2671–2672.
27.
Fortin G, Yurchenko K, Collette C, et al. L-Carnitine, a diet component and organic cation transporter OCTN ligand, displays immune suppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009; 156: 161-171.
28.
Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. Am J Kidney Dis 2004; 44: 715-719.
29.
Tanvir S, Butt G-D, Taj R. Prevalence of Depression and Anxiety in Chronic Kidney Disease Patients on Haemodialysis. Ann Pak Inst Med Sci 2013; 9: 64-67.
30.
Lotfy HM, Sabry SM, Ghobrial EE, et al. The effect of regular hemodialysis on the nutritional status of children with end-stage renal disease. Saudi Journal of Kidney Diseases and Transplantation 2015; 26: 263.
31.
Mortazavi M, Seirafian S, Eshaghian A, et al. Associations of oral L-carnitine with hemoglobin, lipid profile, and albumin in hemodialysis patients. J Res Med Sci 2012; 17: 33-37.
32.
Bellinghieri G, Savica V, Mallamace A, et al. Correlation between increased serum and tissue L -carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr 1983; 38: 523-531.
33.
Steiber AL, Davis AT, Spry L, et al. Carnitine treatment improved quality-of-life measure in a sample of Midwestern hemodialysis patients. JPEN J Parenter Enteral Nutr 2006; 30: 10-15.
34.
Kletzmayr J, Mayer G, Legenstein E. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int 1999; 55: S93-S106.
35.
Murphy WJA, Steiber A, Connery GC, et al. Altered carnitine metabolism in dialysis patients with reduced physical function may be due to dysfunctional fatty acid oxidation. Nephrol Dial Transplant 2012; 27: 304–310.
36.
Labonia WD. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26: 757-764.
37.
Bilal A, Etienne B, Renata V, et al. L-carnitine supplementation and EPO requirement in children on chronic hemodialysis. Pediatric Nephrology 2010; 25: 557-560.
38.
Sabry AA. The role of oral L-Carnitine therapy in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2010; 21: 454-459.
39.
Vaux E, Taylor DJ, Altman P, et al., Effect of carnitine supplementation on muscle metabolism by the use of magnetic resonance spectroscopy and near-infrared spectroscopy in end-stage renal disease. Nephron Clin Pract 2004; 97: 41-48.
40.
Lilien MR, Duran M, Quak JM, et al. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 2000; 15: 17-20.
41.
Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37: S66-70.
42.
Savica V, Santoro D, Mazzaglia G. L-carnitine Infusions May Suppress Serum C-Reactive Protein and Improve Nutritional Status in Maintenance Hemodialysis Patients. J Ren Nutr 2005; 15: 225-230.
43.
Kidney disease: Improving Global Outcomes (KDIGO):Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease August 2012 Kidney International Supplements 2: 279-335.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
